NYSE: BTI$ 55.84(0.522)
BAT’s US Bio-tech arm, Kentucky BioProcessing (KBP) today announced plans to commence a Phase I first-time-in-human study of its COVID-19 vaccine candidate following approval of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA). Enrollment for the study is expected to begin shortly. Full press release, intended for use by the media only, available … Continued
For the 19th year in a row, British American Tobacco (BAT) has been named in the Dow Jones Sustainability Index – the only tobacco company to be included on the prestigious list. This announcement is a further demonstration of BAT’s continued commitment to its purpose to build A Better Tomorrow by reducing the health impact of its … Continued
Grouped Alto applications are final FDA submission for deemed products, representing both Vuse and VELO portfolios Reynolds completes 2020 deemed product PMTA submissions for one of the broadest portfolios in the industry Reynolds has provided the FDA with more than 530,000 pages of scientific data for review as part of all PMTA applications submitted More … Continued
VELO pouch is second group of PMTAs for VELO products, and completes current VELO brand PMTA submissions WINSTON-SALEM, NC. September 1, 2020 – Reynolds American Inc. (“Reynolds”) announces today the submission of a group of Premarket Tobacco Product Applications (“PMTAs”) to the U.S. Food and Drug Administration (“FDA”) seeking orders authorizing the marketing of VELO pouches. … Continued
FDA applications are a first for VELO’s dissolvable nicotine lozenges WINSTON-SALEM, N.C. – August 24, 2020 – Reynolds American Inc. (“Reynolds”) announces today the submission of a group of Premarket Tobacco Product Applications (“PMTAs”) to the U.S. Food and Drug Administration (“FDA”) seeking orders authorizing the marketing of VELO dissolvable nicotine lozenges. A grant of … Continued
Vuse Vibe and Vuse Ciro join Reynolds’ Prior Vuse Solo Submission to FDA WINSTON-SALEM, N.C. – April 15, 2020 – Reynolds American (“Reynolds”) announced today that it has submitted two new Premarket Tobacco Product Applications (“PMTAs”) to the U.S. Food and Drug Administration (“FDA”). Reynolds is seeking marketing orders for their Vuse Vibe and Vuse … Continued
Potential vaccine in development for COVID-19 using new, fast-growing tobacco plant technology – pre-clinical testing under way Tobacco plants offer the potential for faster and safer vaccine development compared to conventional methods Potential to manufacture 1-3 million doses of vaccine per week April 1, 2020: BAT’s US bio-tech subsidiary, Kentucky BioProcessing (KBP), is developing a potential vaccine … Continued
First-of-its-Kind Filing for VUSE Products WINSTON-SALEM, N.C. – Nov. 27, 2019 – Today, Reynolds American Inc. (“RAI”) announced that the recently-submitted Premarket Tobacco Product Application (“PMTA”) for VUSE vapor products has been filed by the Food and Drug Administration (“FDA”) for substantive scientific review, moving the application one step further through the review process. … Continued
WINSTON-SALEM, N.C. – Oct. 11, 2019 – Reynolds American Inc. (“Reynolds”) today announced submission of a Premarket Tobacco Product Application (“PMTA”) through one of its subsidiaries to the U.S. Food and Drug Administration (FDA) seeking orders authorizing the marketing of VUSE Electronic Nicotine Delivery Systems (ENDS) products. VUSE products offer a cartridge-based vapor system intended for adult … Continued
Company expands the rollout of VELO as part of its innovative Modern Oral portfolio to meet the evolving preferences of today’s adult tobacco consumer with simple, hassle-free, oral nicotine products. Product expansion furthers RJRVC’s commitment to transforming tobacco by leading the charge on responsible innovation in the industry. WINSTON-SALEM, N.C. – July 8, 2019 – R.J. … Continued